ERFSF
Price
$60.70
Change
+$0.17 (+0.28%)
Updated
Oct 17 closing price
SIBN
Price
$13.06
Change
+$0.25 (+1.95%)
Updated
Oct 18, 11:40 AM (EDT)
17 days until earnings call
Ad is loading...

ERFSF vs SIBN

Header iconERFSF vs SIBN Comparison
Open Charts ERFSF vs SIBNBanner chart's image
Eurofins Scientific Nante
Price$60.70
Change+$0.17 (+0.28%)
Volume$1.67K
CapitalizationN/A
SI-BONE
Price$13.06
Change+$0.25 (+1.95%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
ERFSF vs SIBN Comparison Chart
Loading...
SIBN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ERFSF vs. SIBN commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERFSF is a Sell and SIBN is a StrongSell.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (ERFSF: $60.70 vs. SIBN: $12.81)
Brand notoriety: ERFSF and SIBN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ERFSF: 200% vs. SIBN: 64%
Market capitalization -- ERFSF: $13.29B vs. SIBN: $672.23M
ERFSF [@Medical Specialties] is valued at $13.29B. SIBN’s [@Medical Specialties] market capitalization is $672.23M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERFSF’s FA Score shows that 1 FA rating(s) are green whileSIBN’s FA Score has 0 green FA rating(s).

  • ERFSF’s FA Score: 1 green, 4 red.
  • SIBN’s FA Score: 0 green, 5 red.
According to our system of comparison, ERFSF is a better buy in the long-term than SIBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SIBN’s TA Score shows that 4 TA indicator(s) are bullish.

  • SIBN’s TA Score: 4 bullish, 5 bearish.

Price Growth

ERFSF (@Medical Specialties) experienced а +0.98% price change this week, while SIBN (@Medical Specialties) price change was -1.99% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.

Reported Earning Dates

SIBN is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Medical Specialties (-2.01% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERFSF($13.3B) has a higher market cap than SIBN($672M). ERFSF YTD gains are higher at: -5.617 vs. SIBN (-38.971). ERFSF has higher annual earnings (EBITDA): 1.49B vs. SIBN (-34.45M). ERFSF has more cash in the bank: 487M vs. SIBN (166M). SIBN has less debt than ERFSF: SIBN (39M) vs ERFSF (3.33B). ERFSF has higher revenues than SIBN: ERFSF (6.71B) vs SIBN (139M).
ERFSFSIBNERFSF / SIBN
Capitalization13.3B672M1,979%
EBITDA1.49B-34.45M-4,337%
Gain YTD-5.617-38.97114%
P/E Ratio19.27N/A-
Revenue6.71B139M4,829%
Total Cash487M166M293%
Total Debt3.33B39M8,526%
FUNDAMENTALS RATINGS
ERFSF vs SIBN: Fundamental Ratings
ERFSF
SIBN
OUTLOOK RATING
1..100
5910
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
45
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
4984
P/E GROWTH RATING
1..100
84100
SEASONALITY SCORE
1..100
18n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERFSF's Valuation (16) in the null industry is in the same range as SIBN (45) in the Medical Specialties industry. This means that ERFSF’s stock grew similarly to SIBN’s over the last 12 months.

ERFSF's Profit vs Risk Rating (84) in the null industry is in the same range as SIBN (100) in the Medical Specialties industry. This means that ERFSF’s stock grew similarly to SIBN’s over the last 12 months.

ERFSF's SMR Rating (94) in the null industry is in the same range as SIBN (95) in the Medical Specialties industry. This means that ERFSF’s stock grew similarly to SIBN’s over the last 12 months.

ERFSF's Price Growth Rating (49) in the null industry is somewhat better than the same rating for SIBN (84) in the Medical Specialties industry. This means that ERFSF’s stock grew somewhat faster than SIBN’s over the last 12 months.

ERFSF's P/E Growth Rating (84) in the null industry is in the same range as SIBN (100) in the Medical Specialties industry. This means that ERFSF’s stock grew similarly to SIBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SIBN
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
SIBN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL232.150.37
+0.16%
Apple
SPY582.350.05
+0.01%
SPDR® S&P 500® ETF Trust
TSLA220.89-0.44
-0.20%
Tesla
BTC.X67399.836000-212.882810
-0.31%
Bitcoin cryptocurrency
GME21.41-0.25
-1.15%
GameStop Corp

ERFSF and

Correlation & Price change

A.I.dvisor tells us that ERFSF and RGEN have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ERFSF and RGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERFSF
1D Price
Change %
ERFSF100%
-0.79%
RGEN - ERFSF
24%
Poorly correlated
+2.87%
SIBN - ERFSF
24%
Poorly correlated
-3.10%
SOAGY - ERFSF
22%
Poorly correlated
+15.19%
SAUHY - ERFSF
22%
Poorly correlated
-2.43%
RMD - ERFSF
21%
Poorly correlated
+0.52%
More

SIBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SIBN has been loosely correlated with KIDS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SIBN jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SIBN
1D Price
Change %
SIBN100%
-3.10%
KIDS - SIBN
49%
Loosely correlated
-3.21%
FNA - SIBN
45%
Loosely correlated
-5.66%
UTMD - SIBN
41%
Loosely correlated
-0.88%
QTRX - SIBN
41%
Loosely correlated
-3.12%
LUNG - SIBN
40%
Loosely correlated
-5.74%
More